Skip to main content

Table 2 Systemic pharmacological treatments other than biologicals assumed during the study observation period for psoriatic arthritis or psoriasis

From: Real-world evidence of biologic treatments in psoriatic arthritis in Italy: results of the CHRONOS (EffeCtiveness of biologic treatments for psoriatic artHRitis in Italy: an ObservatioNal lOngitudinal Study of real-life clinical practice) observational longitudinal study

 

N (%)

Patients receiving other pharmacological therapies for psoriatic arthritis or psoriasis during the observation period

186 (46.6%)

Methotrexate

112 (28.1%)

NSAIDs

49 (12.3%)

Systemic corticosteroids (oral or parenteral)

43 (10.8%)

Leflunomide

18 (4.5%)

Sulfasalazine

15 (3.8%)

Cyclosporine

7 (1.8%)

Apremilast

4 (1.0%)

Azathioprine

1 (0.3%)

  1. NSAIDs: non-steroidal anti-inflammatory drugs
  2. Percentages calculated over the total number of eligible patients (N = 399)